Claims for Patent: 9,539,258

Summary for Patent: 9,539,258

Title:	Quinazoline derivatives for the treatment of cancer diseases
Abstract:	The present invention relates to the use of quinazolines of formula (I), ##STR00001## wherein the groups R.sup.a to R.sup.d have the meanings given in the claims and specification, in cancer therapy.
Inventor(s):	Solca; Flavio (Vienna, AT), Amelsberg; Andree (Southbury, CT), van Meel; Jacobus C. A. (Moedling, AT), Baum; Anke (Moedling, AT), Stehle; Gerd (Ehingen, DE)
Assignee:	Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:	14/739,299
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,539,258
Patent Claims:	1. A method for treating metastatic non-small cell lung cancer (NSCLC) of squamous histology in a second line patient having failed at least one prior chemotherapy regimen, the method comprising administering to said patient a therapeutically effective amount of the compound 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-bute- n-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, or a physiologically acceptable salt thereof. 2. The method of claim 1, wherein the 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-bute- n-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, or a physiologically acceptable salt thereof, is used in monotherapy or in combination with another anti-tumour therapeutic agent. 3. The method of claim 2, wherein the other anti-tumour therapeutic agent is selected from the group consisting topoisomerase inhibitors, mitosis inhibitors, compounds which interact with nucleic acids, hormone antagonists, inhibitors of metabolic processes, cytokines, and antibodies. 4. The method of claim 2, wherein the other anti-tumour therapeutic agent is cis-platinum. 5. The method of claim 2, wherein the compound is 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-bute- n-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline dimaleate.